Dr Reddy's Laboratories, the second largest pharmaceutical company in India, has launched zafirlukast tablets, a bioequivalent generic version of Accolate in the US market with range of 10 mg and 20 mg. According to IMS study, zafirlukast had total US sales of approximately $50 million for the 12 months ending August 31, 2010.
DRL received the US District Court of New Jersey permission against its motion for summary judgment of non-infringement against AstraZeneca on November 15 and then it received US FDA approval for zafirlukast tablets on November 18, 2010.